Delayed-onset and long-lasting severe neutropenia due to rituximab.
Swiss Med Wkly
; 134(5-6): 79-80, 2004 Feb 07.
Article
em En
| MEDLINE
| ID: mdl-15113056
ABSTRACT
BACKGROUND:
Rituximab, a monoclonal antibody, is effective in CD20-positive B-cell lymphoma and is now widely used either as a single agent or in combination with chemotherapy. The antibody's toxicity is generally mild and transient. There are reports of protracted neutropenia in patients treated with rituximab. CASE REPORT We report on a patient with Burkitt's lymphoma treated with the hyper-CVAD chemotherapy regimen combined with rituximab. Four weeks after the five months' treatment marked neutropenia and hypogammaglobulinaemia occurred and persisted for one year. Both laboratory findings were not associated with severe infections in our patient.CONCLUSIONS:
Delayed-onset neutropenia is a newly recognised toxicity of rituximab treatment which may last up to one year and be complicated by serious infections.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vincristina
/
Dexametasona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Linfoma de Burkitt
/
Ciclofosfamida
/
Anticorpos Monoclonais
/
Neutropenia
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Swiss Med Wkly
Assunto da revista:
MEDICINA
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Suíça